Long-form analysis at the intersection of AI and life sciences — all spells, sorted by time.
The brain slows and dulls with age. Could a drug flip a single switch and turn that around? A 2026 review puts its bet on SIRT1, the NAD⁺-dependent enzyme whose depletion in the brain is tied to cognitive decline and dementia. Promising, but still far from a human prescription.
You took NMN for three months and still look the same in the mirror. Why? Three landmark studies piece together how NAD⁺ collapses with age: how cells fake hypoxia, who eats your supplements, and whether topping NAD⁺ back up can truly rejuvenate old cells.
We've heard plenty of mouse stories about NAD⁺ falling with age. Three studies finally move it onto real humans: a tube of blood, a brain scan, and a randomized double-blind trial each confirm NAD⁺ truly declines in us, while honestly flagging that the clinical payoff is still unsettled.
A single AI Agent is reliable. But your cognitive bandwidth caps at 5 parallel threads. Skill Graphs 2.0 introduces a three-layer architecture — atoms (deterministic), molecules (fixed sequence), compounds (strategic autonomy) — turning 5 compound-level tasks into 500 work units. This article breaks down the framework, practical principles, and known limitations.
The pitch writes itself: as you age, cellular NAD+ levels decline, mitochondria lose their fuel, and muscles begin to waste away. Take NMN or NR daily, restore
There's an old saying in software engineering: the hardest bug to fix isn't the one that crashes the system — it's the one that lets the system look like it's